Synthorx Throws THOR-707 Into Competitive IL-2 Space With HAMMER, Its First-Ever Clinical Trial
Emerging Company Profile: This is the first human study for lead product candidate THOR-707 and for the company's Expanded Genetic Alphabet platform, starting with a recombinant IL-2 that's being tested in solid tumors.
You may also be interested in...
Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Syncona and Novartis Venture Fund have invested CHF35m in Anaveon, which reckons it can overcome the toxicity and half-life limitations of the cytokine interleukin-2 to enhance the body’s immune response to tumors.